NCT00532207已完成3 期
Efficacy and Safety of Teriparatide 20 Micrograms in the Treatment of Postmenopausal Women With Osteoporosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- To test the hypothesis that therapy for 12 months with once daily subcutaneous PTH 1-34 (teriparatide; TPTD) 20 micrograms will increase Bone Mineral Density (BMD) at the lumbar spine in postmenopausal women with osteoporosis
研究概览
简要总结
To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Are postmenopausal women at least 55 years old and at least 2 years postmenopausal at the time of entry into the trial, and who have given informed consent before entering the study and after being informed of the risks, medications, and procedures to be used in the study. In addition, women below the age of 60 years with indeterminate menopause due to premenopausal hysterectomy must have their postmenopausal status confirmed with a serum FSH level > 30 IU/L.
- •Posterior-anterior lumbar spine (L1-L4) BMD and/or femoral neck BMD measurement at least < 2.5 standard deviation (SD) from the mean of healthy, pre-menopausal women.
- •Results of lumbar BMD (L1-L4) measurement must be available. The initial lumbar spine assessment and the determination of the patient's eligibility for entry into the screening phase will be made by the individual investigator. If the L-1 vertebra cannot be analyzed due to artifact, vertebral fracture, osteophytes, or other abnormalities, that vertebra should be excluded from the analysis.
- •Normal or clinically insignificant abnormal laboratory values (as defined by the investigator) including serum calcium, 25 hydroxyvitamin D levels and alkaline phosphatase.
- •Willing to be trained on and use a pen type injection delivery system on a daily basis for 12 months.
排除标准
- •Active liver disease - liver enzymes (ALT, AST) more than three times the upper normal range, or a bilirubin of > 2.0 mg/dl, or clinical jaundice.
- •Abnormal thyroid function not corrected by therapy. Normal thyroid function will be documented by a normal TSH during screening phase
- •History of active nephrolithiasis or urolithiasis in the prior 2 years. Patients with any documented history of nephro- or urolithiasis must have had an appropriate imaging procedure within the prior 6 months, such as, an intravenous pyelography (IVP), supine radiograph of the kidney ureter bladder (KUB), or renal ultrasound, which must document the absence of stones
- •History of malignant neoplasms within the prior 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. If malignant neoplasm was ever diagnosed, patient must presently be free of disease.
- •Current pharmacological treatment for osteoporosis, other than calcium and Vitamin D
- •History of Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption
研究组 & 干预措施
A
Experimental
干预措施: teriparatide (Drug)
结局指标
主要结局
To test the hypothesis that therapy for 12 months with once daily subcutaneous PTH 1-34 (teriparatide; TPTD) 20 micrograms will increase Bone Mineral Density (BMD) at the lumbar spine in postmenopausal women with osteoporosis
次要结局
- To test the hypothesis that treatment with TPTD will favorably affect quality of life within the natural course of the disease
- To test the hypothesis that therapy for 3 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis
- To test the hypothesis that therapy for 12 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis.
- To evaluate safety of once daily subcutaneous teriparatide 20 micrograms for 12 months.
- To evaluate effect of teriparatide on changing in femoral neck and total hip BMD
- To test the hypothesis that treatment with TPTD will favorably affect back pain within the natural course of the disease
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Teriparatide (PTH) and Bone Strength in Postmenopausal WomenOsteoporosisNCT01155245University Health Network, Toronto60
已完成
4 期
Bone Marker Changes With Teriparatide/Postmenopausal OsteoporosisOsteoporosis, Post-MenopausalNCT00532545Eli Lilly and Company45
已完成
3 期
Phase 3 Clinical Trial of Teriparatide in JapanOsteoporosisNCT00433160Eli Lilly and Company207
已完成
4 期
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With OsteoporosisOsteoporosis, PostmenopausalNCT00035256Eli Lilly and Company330
已完成
3 期
Bone Effects of Teriparatide Following AlendronateOsteoporosisNCT00191893Eli Lilly and Company66